医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promethera Biosciences Establishes Branch Office in Tokyo

2018年05月15日 PM03:00
このエントリーをはてなブックマークに追加


 

MONT-SAINT-GUIBERT, Belgium & TOKYO

Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the foundation of a new branch office in Tokyo, Promethera Biosciences Japan Branch Ltd. Establishing a branch office in Japan marks the starting point for building a strong presence of Promethera in Japan first, initially focusing on increased Business Development, Investor Relations activities and expansion of its business and products pipeline in Japan, this presence will also address the Asian markets as a second step

“Today, we took another significant step as a global innovator in the liver disease space and are consistently pursuing our vision and strategy. Adding a local presence in Japan, in addition to our corporate headquarters and growing product development organization in Belgium, our US operations and manufacturing center of excellence in the North Carolina Research Triangle, as well as our newly announced Swiss subsidiary Baliopharm AG represents a key milestone for Promethera in continuing to establish an international footprint,” commented John Tchelingerian, PhD, President & CEO of Promethera Biosciences SA.

The Asian markets, and particularly the Japanese one, regard cell therapy positively and represent a special opportunity for Promethera’s products and corporate development activities. The Company has benefitted from the positive climate in Japan and South Korea in the past and was able to attract a significant set of both strategic and institutional investors from these prominent countries in cell therapies, including Mitsui & Co. Global Investment, Mitsubishi UFJ Capital Co., Ltd., Cell Innovation Partners, L.P., Shibuya Corporation and Shinsei Corporate Investment from Japan, and LifeLiver Co., Ltd. from South Korea. Promethera is committed to build on these strong initial ties and continue expanding its network in Japan, South Korea and the wider Asian region.

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of R&D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, NC, USA.

Promethera®, HepaStem®, H2stem®, Cytonet®, Heparesc® are all registered trademarks of the PROMETHERA group.

https://www.linkedin.com/company/promethera-biosciences

https://twitter.com/Promethera

View source version on businesswire.com: https://www.businesswire.com/news/home/20180514006367/en/

CONTACT

Promethera Biosciences SA
Alexandra Schiettekatte
Alexandra.schiettekatte@promethera.com
www.promethera.com
or
For
media:

MacDougall Communications
Mario Brkulj or Shai Biran
+49
89 2420 9345
or +1 781-235-3060
promethera@macbiocom.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Dr. Reddy’s Q4 and FY18 Financial Results
  • 武田薬品が米国臨床腫瘍学会(ASCO)と欧州血液学会(EHA)の年次総会でオンコロジーの広範なポートフォリオとパイプラインのデータを発表
  • ResMed赞助的研究显示,采用居家吸氧与居家无创通气相结合治疗COPD具有成本效益
  • 武田在美国临床肿瘤学会(ASCO)和欧洲血液学会(EHA)年会上重点介绍其强大的肿瘤产品阵容和后续产品线数据
  • AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model